King Pharmaceuticals KG Other (predominantly Europe) — Net premiums written

Other geography segments

North America

-$80K—

Similar metrics at other companies

ACICNet premiums written

$80.58M+16.1%

ACGLOther — Net premiums written

$70M-3.1%

GLRENet premiums written

$183.47M-16.4%

AXSInsurance — Net premiums written

$1.29B+23.8%

CVCONet premiums written

$17M+0.5%

EIGNet premiums written

$187.53M-2.5%

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PremiumsWrittenNet.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's other (predominantly europe) — net premiums written.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's other (predominantly europe) — net premiums written?: King Pharmaceuticals (KG) reported other (predominantly europe) — net premiums written of $1.57M in Q4 2025.
What does other (predominantly europe) — net premiums written mean?: This metric reflects the gross premiums written by the segment minus the portion ceded to reinsurers. It provides a clearer view of the company's retained risk and the actual premium volume it keeps on its own balance sheet. This is a critical measure for evaluating the company's underwriting strategy and risk retention appetite within this geographic territory.